Overview

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To compare patient perceptions of the sensory attributes, including taste and aftertaste, of Olopatadine relative to azelastine when administered as a single dose in patients with allergic rhinitis.
Phase:
Phase 4
Details
Lead Sponsor:
Alcon Research
Treatments:
Azelastine
Olopatadine Hydrochloride